Literature DB >> 17130200

Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes.

Helen L Lutgers1, Reindert Graaff, Thera P Links, Lielith J Ubink-Veltmaat, Henk J Bilo, Rijk O Gans, Andries J Smit.   

Abstract

OBJECTIVE: Advanced glycation end products (AGEs) are thought to have a role in the pathogenesis of diabetes complications. We recently reported the association between skin autofluorescence, as a measure of tissue AGE accumulation, and diabetic neuropathy in a selected diabetic population. In this study, we investigated the relation between skin autofluorescence and clinical variables including micro- and macrovascular complications in a type 2 diabetes primary care population. RESEARCH DESIGN AND METHODS: Clinical data and skin autofluorescence were obtained in the type 2 diabetes group (n = 973) and in a control group (n = 231). Skin autofluorescence was assessed by illumination of the lower arm with a fluorescent tube (peak intensity approximately 370 nm).
RESULTS: Skin autofluorescence was significantly higher in type 2 diabetic patients compared with control subjects in each age category. Multiple regression analysis showed significant correlation of skin autofluorescence with age, sex, diabetes duration, BMI, smoking, HbA1c, plasma creatinine, HDL cholesterol, and albumin-to-creatinine ratio in the type 2 diabetes group (R2 = 25%) and with age and smoking in the control group (R2 = 46%). Skin autofluorescence was significantly higher in the type 2 diabetes group, with both micro- and macrovascular disease, compared with the group without complications and the group with only microvascular complications.
CONCLUSIONS: This study confirms in a large group of type 2 diabetic patients that skin autofluorescence is higher compared with age-matched control subjects and is associated with the severity of diabetes-related complications. Skin autofluorescence reflecting vascular damage might be a rapid and helpful tool in the diabetes outpatient clinic for identifying diabetic patients who are at risk for developing complications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17130200     DOI: 10.2337/dc05-2173

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  79 in total

1.  Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients.

Authors:  Mihaela Oleniuc; Adalbert Schiller; Irina Secara; Mihai Onofriescu; Simona Hogas; Mugurel Apetrii; Dimitrie Siriopol; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2011-12-10       Impact factor: 2.370

2.  Usefulness of skin advanced glycation end products to predict coronary artery calcium score in patients with type 2 diabetes.

Authors:  Alejandra Planas; Olga Simó-Servat; Jordi Bañeras; Mónica Sánchez; Esther García; Ángel M Ortiz; Marisol Ruiz-Meana; Cristina Hernández; Ignacio Ferreira-González; Rafael Simó
Journal:  Acta Diabetol       Date:  2021-05-25       Impact factor: 4.280

3.  Optoacoustic detection of tissue glycation.

Authors:  Ara Ghazaryan; Murad Omar; George J Tserevelakis; Vasilis Ntziachristos
Journal:  Biomed Opt Express       Date:  2015-07-31       Impact factor: 3.732

4.  Partial characterization of the molecular nature of collagen-linked fluorescence: role of diabetes and end-stage renal disease.

Authors:  David R Sell; Ina Nemet; Vincent M Monnier
Journal:  Arch Biochem Biophys       Date:  2009-10-30       Impact factor: 4.013

5.  Association of two glyoxalase I gene polymorphisms with nephropathy and retinopathy in Type 2 diabetes.

Authors:  J C Wu; X H Li; Y D Peng; J B Wang; J F Tang; Y F Wang
Journal:  J Endocrinol Invest       Date:  2011-07-07       Impact factor: 4.256

Review 6.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

7.  Accumulation of advanced glycation end (AGEs) products in intensive care patients: an observational, prospective study.

Authors:  Wendela L Greven; Jitty M Smit; Johannes H Rommes; Peter E Spronk
Journal:  BMC Clin Pathol       Date:  2010-05-25

8.  Skin advanced glycation end product accumulation is poorly reflected by glycemic control in type 2 diabetic patients (ZODIAC-9).

Authors:  Esther G Gerrits; Helen L Lutgers; Nanne Kleefstra; Klaas H Groenier; Andries J Smit; Rijk O B Gans; Henk J G Bilo
Journal:  J Diabetes Sci Technol       Date:  2008-07

9.  Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus.

Authors:  H L Lutgers; E G Gerrits; R Graaff; T P Links; W J Sluiter; R O Gans; H J Bilo; A J Smit
Journal:  Diabetologia       Date:  2009-03-10       Impact factor: 10.122

10.  Life expectancy in a large cohort of type 2 diabetes patients treated in primary care (ZODIAC-10).

Authors:  Helen L Lutgers; Esther G Gerrits; Wim J Sluiter; Lielith J Ubink-Veltmaat; Gijs W D Landman; Thera P Links; Reinold O B Gans; Andries J Smit; Henk J G Bilo
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.